Dr. Lin has over 30 years of leadership experience in drug discovery and development within the biotech industry, with a strong focus on oncology and inflammatory diseases. He is deeply committed to developing innovative therapies for conditions with unmet medical needs.

Currently at AgnistaBio, Dr. Lin previously held executive roles including Chief Scientific Officer at AltruBio Inc. and Tianti Biotherapeutics. He was also the Founder, Chairman, and CEO of AbGenomics for nearly two decades. Under his leadership, AbGenomics built a strong culture of scientific collaboration, resulting in six novel therapeutic candidates, seven IND filings, and the successful completion of seven clinical trials. Notably, the company’s lead compound showed clinical efficacy in four distinct diseases.

Earlier in his career, Dr. Lin was a founding Professor and Director of the Graduate Institute of Immunology at National Taiwan University College of Medicine. His academic work included supervising physician-scientists across multiple disciplines and publishing over 50 peer-reviewed articles. He also served as Associate Editor for the Journal of Biomedical Science and on the Editorial Board of International Immunopharmacology.

Dr. Lin earned his Diplom degree (Summa Cum Laude) and Doctorate in Immunology (Magna Cum Laude) from the University of Tübingen, Germany, with a multidisciplinary focus on biotechnology, immunology, molecular genetics, and phytopharmaceuticals. His research was conducted at prestigious institutions including the Max Planck Institute for Immunogenetics, the Basel Institute for Immunology, and the Howard Hughes Medical Institute at Yale University.

Dr. Lin is the named inventor of more than 20 global patents and continues to be a key contributor to therapeutic innovation in biotech.